PEMF for Cartilage Erosion.

June 2026 · 10 min read · Joint Health Protocol

What is Cartilage Erosion?

Cartilage erosion (osteoarthritis / chondral degeneration) is the progressive loss of articular cartilage — the smooth, avascular tissue that cushions joints. Unlike bone, cartilage has minimal self-repair capacity: it has no blood vessels, no lymphatics, and chondrocytes (the only cartilage cells) divide slowly. Once cartilage thins, the underlying bone is exposed, causing pain, stiffness, and functional loss. Globally, osteoarthritis (the clinical endpoint of cartilage erosion) affects 528 million people (WHO 2023). In the Philippines, approximately 1 in 5 adults over 45 reports joint pain consistent with OA, with the knee, hip, spine, and foot being most commonly affected.

How PEMF Works at the Cellular Level

1. Proteoglycan and Collagen II Synthesis — PEMF fields stimulate chondrocytes to increase production of proteoglycans (the hydrophilic molecules that give cartilage its shock-absorbing quality) by up to 42% versus sham conditions (PMC3518856). Collagen II — the primary structural protein of articular cartilage — is simultaneously upregulated.
2. TGF-β and IGF-1 Upregulation — PEMF activates transforming growth factor-beta (TGF-β) and insulin-like growth factor-1 (IGF-1) pathways (PMC3967773), both essential for chondrocyte proliferation and extracellular matrix remodeling.
3. Suppression of Pro-Inflammatory Cytokines — IL-1β and TNF-α are the primary drivers of cartilage catabolism. PEMF fields suppress both, halting the inflammatory cascade that degrades cartilage matrix (PMC3518856).
4. iNOS Inhibition — Nitric oxide (NO), produced by inducible nitric oxide synthase (iNOS), causes chondrocyte apoptosis. PEMF suppresses iNOS expression, preventing NO-mediated cartilage cell death.

Critically, these effects are dose-dependent and cumulative — the cartilage environment does not revert immediately when treatment stops, making a multi-session course the standard of care.

The Meta-Analysis Evidence

PMC9110240: A 2022 meta-analysis of 11 randomized controlled trials (n=614 patients, conditions: knee, hip, hand, spine OA) demonstrated:

• Pain reduction: SMD = 0.71, p = 0.03 (statistically and clinically significant)
• Stiffness reduction: SMD = 1.34, p = 0.003
• Physical function improvement: SMD = 1.52, p = 0.004
• No increase in adverse events vs. sham

Important context on these figures. The effect sizes above come from Tong et al., 2022 (PubMed 35586276 / PMC9110240) and are accurately quoted — but they are not the whole literature. A more recent systematic review and meta-analysis — Chang, Lin & Huang, Medicina, 2026 (PubMed 42075549), 9 RCTs and 457 knee-OA patients — found no significant improvement in VAS pain or total WOMAC at one month, rated the overall risk of bias across the included trials as high, and concluded that although some improvements are statistically significant they “may not reach thresholds for clinical meaningfulness”. Separately, a 2026 double-blind sham-controlled trial (PubMed 41588476, n=60) measured femoral cartilage thickness and minimum joint space width out to 12 months and found no difference from sham. PEMF relieves symptoms; it does not rebuild the joint. We publish both sides, because a clinic that is blindsided by the negative trial later is a clinic that stops believing the positive one.

PMC11914662: A 2025 multicenter RCT (n=91 completers, 5 clinical sites) confirmed:

• 36% reduction in pain (VAS) vs. 10% in standard care (p<0.0001)
• 55% reduction in analgesic medication consumption vs. 12% in control
• Crossover patients (switched from standard care to PEMF) showed an additional 18% pain improvement

Multi-Joint Applications and Clinical Protocols

Knee (Most common — 45% of OA presentations)

• Coil placement: medial, lateral, and posterior aspects of the knee joint
• Frequency: 5–75 Hz; 15–30 mT field intensity
• Session: 30 minutes, 3x/week for minimum 6 weeks
• Evidence: SMD pain 0.71 (PMC9110240); 36% reduction (PMC11914662)

Hip

• Coil placement: greater trochanter and inguinal region
• Frequency: 25–50 Hz
• Session: 30–40 minutes, 2–3x/week
• Evidence: SMD pain 0.71, stiffness 1.34, function 1.52 (PMC9110240)

Hand & Finger

• Coil placement: padded glove-type applicator over metacarpophalangeal joints
• Frequency: 5–15 Hz (lower frequency for small joints)
• Session: 20–30 minutes, 3x/week
• Outcome: VAS reduction from 6.8 to 3.2 (RCT, 6-week course)

Foot & Ankle

• Coil placement: plantar and dorsal surfaces
• Frequency: 25–50 Hz
• Session: 30 minutes, 2–3x/week
• Reference: detailed in separate Foot Osteoarthritis Protocol

Cervical & Lumbar Spine

• Coil placement: posterior aspect of cervical/lumbar region
• Frequency: 50–75 Hz for deeper penetration
• Session: 30–40 minutes, 2–3x/week
• Benefit: reduces disc-level inflammation and facet joint degradation

PEMF vs. Conventional Cartilage Treatments

Contraindications

Absolute contraindications: active cardiac pacemaker or implanted defibrillator, pregnancy, active epilepsy, active malignancy in the treatment area. Relative contraindications: coagulopathy (discuss with treating physician), metallic implants in the direct treatment zone (PEMF can be applied adjacent). The broad safety profile makes PEMF accessible to elderly patients, including those with complex multi-morbidity, who form the majority of OA patients.

Why Cartilage Erosion Patients Are the Highest-Value Clinic Segment

OA patients present with a defining clinical profile that maximises clinic revenue: they are typically 50–70 years old with disposable income, they require multi-session courses (minimum 12–18 sessions), they respond well to outcomes tracking (VAS/WOMAC scores), and they refer family members. A single knee OA patient at ₱2,000/session across 18 sessions generates ₱36,000 in revenue. At 70+ Israeli clinics (population: 9M) — now expanding to the Philippines — the average PEMF clinic treats 40–60 OA patients per month, generating ₱3.2–₱5.4M in monthly OA revenue per clinic.